EOLS Q2 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$69M+3.7% YoY

Gross Profit

$45M65.3% margin

Operating Income

-$10M-14.7% margin

Net Income

-$17M-24.7% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$229M

Total Liabilities

$247M

Stockholders' Equity

-$19M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$67M	+3.7%
Gross Profit	$45M	$47M	-3.7%
Operating Income	-$10M	-$8M	-32.6%
Net Income	-$17M	-$11M	-51.0%

Revenue Segments

Product

$69M99%

Service

$688,0001%